Cargando…

Safety of gadolinium based contrast agents in magnetic resonance imaging-guided radiotherapy – An investigation of chelate stability using relaxometry

BACKGROUND AND PURPOSE: With the introduction of hybrid magnetic resonance linacs (MR-linac), improved imaging has enabled daily treatment adaptation. However, the use of gadolinium based contrast agents (GBCAs) is desired to further improve MR image contrast. GBCAs are in the form of a non-toxic me...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahmood, Faisal, Nielsen, Ulla Gro, Jørgensen, Christian Brandt, Brink, Carsten, Thomsen, Henrik S., Hansen, Rasmus Hvass
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8885577/ https://www.ncbi.nlm.nih.gov/pubmed/35243039 http://dx.doi.org/10.1016/j.phro.2022.02.015

Ejemplares similares

An NMR relaxometry approach for quantitative investigation of the transchelation of gadolinium ions from GBCAs to a competing macromolecular chelator
por: Werner, Patrick, et al.
Publicado: (2021)

The effect of gadolinium-based contrast agent administration on magnetic resonance fingerprinting-based T(1) relaxometry in patients with prostate cancer
por: Sushentsev, Nikita, et al.
Publicado: (2020)

Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents
por: Rees, Julian A., et al.
Publicado: (2018)

Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment
por: Le Duc, Géraldine, et al.
Publicado: (2014)

Distribution of Gadolinium in Rat Heart Studied by Fast Field Cycling Relaxometry and Imaging SIMS
por: Bonechi, Claudia, et al.
Publicado: (2019)

Nephrogenic systemic fibrosis (NSF): a late adverse reaction to some of the gadolinium based contrast agents
por: Thomsen, Henrik S., et al.
Publicado: (2007)

A Comprehensive Introduction to Magnetic Resonance Imaging Relaxometry and Contrast Agents
por: Alzola-Aldamizetxebarria, Saioa, et al.
Publicado: (2022)

Gadolinium contrast agents: Over exposure?
por: Biederman, Robert W, et al.
Publicado: (2016)

Impact of brain tumors and radiotherapy on the presence of gadolinium in the brain after repeated administration of gadolinium-based contrast agents: an experimental study in rats
por: Jost, Gregor, et al.
Publicado: (2019)

Dextran-based Nanomicelle System with Directly Ester-bound Gadolinium Chelates as a Magnetic Resonance Imaging Contrast Agent for Tumor Detection
por: Ma, Lirong, et al.
Publicado: (2020)

Gadolinium-DTPA: A New Contrast Agent
por: Niendorf, H. P.
Publicado: (1988)

Chelation of gadolinium with deferoxamine in a patient with nephrogenic systemic fibrosis
por: Leung, Nelson, et al.
Publicado: (2009)

Linear Gadolinium-Based Contrast Agents Are Associated With Brain Gadolinium Retention in Healthy Rats
por: Robert, Philippe, et al.
Publicado: (2016)

Sample Shuttling Relaxometry of Contrast Agents: NMRD Profiles above 1 T with a Single Device
por: Gossuin, Yves, et al.
Publicado: (2016)

Gadolinium Complexes as Contrast Agent for Cellular NMR Spectroscopy
por: Sakol, Nat, et al.
Publicado: (2020)

Mesoporous Silica Nanoparticles with Co-Condensed Gadolinium Chelates for Multimodal Imaging
por: Taylor-Pashow, Kathryn M. L., et al.
Publicado: (2011)

Comparison of linear versus macrocyclic gadolinium chelates in rat skeletal muscle
por: Balik, Mehmet Sabri, et al.
Publicado: (2022)

The presence of the gadolinium-based contrast agent depositions in the brain and symptoms of gadolinium neurotoxicity - A systematic review
por: Olchowy, Cyprian, et al.
Publicado: (2017)

Gadolinium deposition in the brain of dogs after multiple intravenous administrations of linear gadolinium based contrast agents
por: Richter, Henning, et al.
Publicado: (2020)

Biocompatible Polyhydroxyethylaspartamide-based Micelles with Gadolinium for MRI Contrast Agents
por: Jeong, Sang Young, et al.
Publicado: (2010)

Immediate reaction to gadolinium based contrast agent with fatal outcome()()()
por: Behzadi, Ashkan Heshmatzadeh, et al.
Publicado: (2018)

Gadolinium-Based Contrast Agents Hypersensitivity: A Case Series
por: Nucera, Eleonora, et al.
Publicado: (2021)

Gadolinium-based contrast agents in neurofibromatosis type 1 (Review)
por: Năstase, Florentina, et al.
Publicado: (2021)

Recent Advances in Gadolinium Based Contrast Agents for Bioimaging Applications
por: Fatima, Atiya, et al.
Publicado: (2021)

The relaxometry hype cycle
por: Stikov, Nikola, et al.
Publicado: (2023)

Radiosensitization with Gadolinium Chelate-Coated Gold Nanoparticles Prevents Aggressiveness and Invasiveness in Glioblastoma
por: Durand, Maxime, et al.
Publicado: (2023)

Geometrical confinement of gadolinium-based contrast agents in nanoporous particles enhances T(1) contrast
por: Ananta, Jeyarama S., et al.
Publicado: (2010)

Gadolinium retention within multiple rat organs after intra-articular administration of gadolinium-based contrast agents
por: Ringler, Michael D., et al.
Publicado: (2021)

Gadolinium Retention in the Brain of Mother and Pup Mouse: Effect of Pregnancy and Repeated Administration of Gadolinium‐Based Contrast Agents
por: Yao, Xiang, et al.
Publicado: (2022)

Hypersensitivity to Gadolinium-Based Contrast Media
por: Gracia Bara, M. Teresa, et al.
Publicado: (2022)

Fatal Allergic Reaction to Gadolinium Contrast
por: Chalise, Som N, et al.
Publicado: (2023)

Non-contrast T(1) and T(2) relaxometry characterizes reperfusion injury of acute MI in swine
por: Ding, Haiyan, et al.
Publicado: (2015)

Quantitative MRI using relaxometry in malignant gliomas detects contrast enhancement in peritumoral oedema
por: Blystad, I., et al.
Publicado: (2020)

Thermal Excitation of Gadolinium-Based Contrast Agents Using Spin Resonance
por: Dinger, Steven C., et al.
Publicado: (2016)

Acute respiratory distress syndrome after the use of gadolinium contrast agent
por: Kerget, Bugra, et al.
Publicado: (2018)

The New Restrictions on the Use of Linear Gadolinium-based Contrast Agents in Japan
por: Kanda, Tomonori
Publicado: (2018)

Effect of different doses of gadolinium contrast agent on clinical outcomes in MS
por: Ackermans, Nathalie, et al.
Publicado: (2019)

Investigating the Impact of Gadolinium-Based Contrast Agents on the Corrected QT Interval
por: Gress, Kyle L, et al.
Publicado: (2020)

PEG-modified gadolinium nanoparticles as contrast agents for in vivo micro-CT
por: Cruje, Charmainne, et al.
Publicado: (2021)

Formation of gadolinium–ferritin from clinical magnetic resonance contrast agents
por: Neburkova, Jitka, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5buvoct0ig610vf3putbivbj1k